/Investor DB

Remiges Ventures, Inc. — 2016 Investments

1 investments dated 2016 · listed companies and verified rows first · show all

Glycomineglycomine.comin𝕏Oct 2016

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.

BiotechSan Francisco, US

Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in

Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalChiesi VenturesCTI Life Sciences Fund L.P.Mission Bay CapitalMission Biocapital+6 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.